| Japanese |
|---|
| Title | ドーパミンD2受容体画像化, 定量化のための125I-IBZMによる基礎的検討 - 平衡法による半定量的評価の検討 - |
|---|
| Subtitle | 短報 |
|---|
| Authors | 外山宏*, 松村要**, 中島弘道**, 市瀬正則***, 倉見美規****, 中川毅**, 前田寿登*, 竹内昭*, 古賀佑彦* |
|---|
| Authors(kana) | |
|---|
| Organization | *藤田保健衛生大学医学部放射線医学教室, **三重大学医学部放射線医学教室, ***トロント大学マウントサイナイ病院放射線科, ****日本メジフィジックス株式会社 |
|---|
| Journal | 核医学 |
|---|
| Volume | 31 |
|---|
| Number | 9 |
|---|
| Page | 1117-1120 |
|---|
| Year/Month | 1994/9 |
|---|
| Article | 報告 |
|---|
| Publisher | 日本核医学会 |
|---|
| Abstract | 「要旨」125I-IBZMのラット脳内動態について検討し, ドーパミンD2受容体の平衡法による半定量法について方法論的検討を行った. 線条体の特異的結合は投与60分後に最大値を示し, 平衡相と考えられた. 理論的にBmax/Kdを反映する線条体/前頭葉比は経時的に上昇した. 123I-IBZMで報告されている数10分間のSPECTによる平衡相を含んだ一回スキャンから線条体/前頭葉比を求める方法では, 真の平衡相でBmax/Kdを求めることにはならないと考えられた. しかし, 平衡相付近の静注後60分の線条体/前頭葉比のプールデータのばらつきが小さかったことから, 静注後の平衡相付近の一定時間の値を比較すれば半定量法の指標となり得ると考えられた. 「I. はじめに」SPECT用のドーパミンD2受容体製剤として開発された123I-(S)-(-)-iodobenzamide(123I-IBZM)は, 欧米を中心に,すでに臨床応用が行われている. |
|---|
| Practice | 臨床医学：一般 |
|---|
| Keywords | 125I-(S)-(-)-3-iodo-2-hydroxy-6-methoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl] benzamide (125I-IBZM), Single photon emission computed tomography (SPECT), Dopamine D2 receptor, Equilibrium analysis, Quantitation. |
|---|
| English |
|---|
| Title | In vivo characteristics of IBZM in Rat Brains : An Agent for Quantitative SPECT Imaging of D2 Dopamine Receptors - A Basis for Semiquantitative Measurement of the Receptor Density Using Equilibrium Analysis - |
|---|
| Subtitle | |
|---|
| Authors | Hiroshi TOYAMA*, Kaname MATSUMURA**, Hiromichi NAKASHIMA**, Masanori ICHISE***, Miki KURAMI****, Tsuyoshi NAKAGAWA**, Hisato MAEDA*, Akira TAKEUCHI*, Sukehiko KOGA* |
|---|
| Authors(kana) | |
|---|
| Organization | *Department of Radiology, Fujita Health University, **Department of Radiology, Mie University, ***Department of Nuclear Medicine, Mount Sinai Hospital, University of Toronto, ****Nihon Medi-Physic Co., Ltd. |
|---|
| Journal | The Japanese Journal of nuclear medicine |
|---|
| Volume | 31 |
|---|
| Number | 9 |
|---|
| Page | 1117-1120 |
|---|
| Year/Month | 1994/9 |
|---|
| Article | Report |
|---|
| Publisher | THE JAPANESE SOCIETY OF NUCLEAR MEDICINE |
|---|
| Abstract | [Summary] To establish a basis for semiquantitative SPECT measurements of the D2 dopamine receptor density using equilibrium analysis, we evaluated in vivo kinetic properties of 125I-IBZM in rat brains. We measured percent uptakes (% dose/g) of 125I-IBZM in the striatum, frontal cortex, and cerebellum. We made these regional measurements at 15, 30, 45, 60, 90, and 120 minutes after injection, respectively. The specific striatal uptake, which is the uptake difference between striatum and frontal cortex or cerebellum, showed a transient equilibrium phase at 60 min. Theoretically, with these 'reversible' D2 receptor binding ligands, the tracer uptake ratio of the striatum-to-frontal cortex or cerebellum during the equilibrium phase provides an estimate of binding potential (Bound/Free=Bmax/Kd). Our experiment showed that these ratio increased with time after bolus injection of the tracer. Striatum to frontal cortex or cerebellum ratios which were calculated with pooled data (n=12) at 60 minutes in equilibrium phase showed nearly constant values (C.V.=12.3% and 13.5%, respectively). Although measuring the striatum to frontal cortex or cerebellum ratios near equilibrium phase by bolus injection of the tracer which are widely used in human SPECT study could not exactly signify the binding Potential, those ratios at fixed time after injection would be reliable for semiquantitative index. |
|---|
| Practice | Clinical medicine |
|---|
| Keywords | 125I-(S)-(-)-3-iodo-2-hydroxy-6-methoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl] benzamide (125I-IBZM), Single photon emission computed tomography (SPECT), Dopamine D2 receptor, Equilibrium analysis, Quantitation. |
|---|